MedTrace Logo

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

NCT04893018 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-06-27

Study results available
· View outcomes & findings →

Summary

This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.

Conditions

  • AIDS-Related Kaposi Sarcoma
  • HIV Infection
  • Kaposi Sarcoma

Interventions

BIOLOGICAL

Efineptakin alfa

Given IM

Sponsors & Collaborators

  • Cancer Immunotherapy Trials Network (CITN)

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Chia-Ching (Jackie) Wang · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2023-12-15
Completion
2023-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893018 on ClinicalTrials.gov